Key points are not available for this paper at this time.
Lenalidomide is clinically active in patients with relapsed or refractory B-CLL. These findings are encouraging and warrant further investigation of this agent in the treatment of this disorder.
Chanan‐Khan et al. (Mon,) studied this question.